Reference 2017-497

REF:            2017-497

Subject:        Biologics and biosimilar prescribing

 

 

Request:

I have a Freedom of Information request regarding biologics and biosimilar prescribing. Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the either dermatology or gastroenterology departments.

 

 

Response:

Number of patients treated Psoriasis Gastroenterology
Abatacept [Orencia] 0 0
Adalimumab [Humira] 0 19
Apremilast [Otezla] 18 0
Baricitinib [Olumiant] 0 0
Certolizumab [Cimzia] 0 0
Etanercept [Enbrel] 0 0
Etanercept Biosimilar [Benepali or Erelzi] 0 0
Golimumab [Simponi] 0 0
Infliximab [Remicade] 0 0
Infliximab Biosimilar [Inflectra, Remsima or Flixabi] 0 102
Rituximab [Mabthera] 0 0
Rituximab Biosimilar [Rixathon or Truxima] 0 0
Secukinumab [Cosentyx] 0 0
Tocilizumab [Ro Actemra] 0 0
Tofacitinib [Xeljanz] 0 0
Ustekinumab [Stelara] 0 0
Vedolizumab [Entyvio] 0 42
Ixekizumab [Taltz] 0 0
These figures do not include Homecare patients.